This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.89% per year. These returns cover a period from January 1, 1988 through March 3, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
medical: Archive
Encompass Health Beats Q1 Earnings Estimates, Ups '25 EPS View
by Zacks Equity Research
EHC's Q1 results benefit on the back of discharge growth and expansion endeavors, partly offset by high operating costs. It currently expects 2025 adjusted EPS from continuing operations within $4.85-$5.10.
HCAPositive Net Change CNCPositive Net Change EHCPositive Net Change ELVPositive Net Change
earnings medical
Doctor's Orders: 4 Hospital Stocks to Benefit From Industry Trends
by Kaibalya Pravo Dey
The Zacks Medical-Hospital industry is likely to gain from growing demand, improving operating stability and finances. Companies like HCA, THC, UHS and CYH are poised to benefit from these trends.
HCAPositive Net Change UHSPositive Net Change THCPositive Net Change CYHPositive Net Change
hospitals medical
HSIC Gears Up for Q1 Earnings: Here's What You Need to Know
by Zacks Equity Research
Henry Schein is expected to report impressive Q1 2025 sales in each of its business segment and a positive pace of recovery from the cyber incident.
HSICNegative Net Change MASINegative Net Change VEEVPositive Net Change HIMSNegative Net Change
earnings medical
BMY Falls 4% Post Q1 Earnings: Should You Buy, Sell or Hold the Stock?
by Ekta Bagri
Bristol Myers' first-quarter performance and raised annual guidance are encouraging. However, we recommend investors to stay on the sidelines as generic competition for legacy drugs and recent pipeline setbacks weigh on the stock.
BMYPositive Net Change PFEPositive Net Change MRKPositive Net Change
biotechnology biotechs earnings-report medical pharmaceuticals
GSK to Report First-Quarter Earnings: Is a Beat in Store?
by Zacks Equity Research
We expect GSK's specialty products like Cabenuva, Juluca, Dovato, Nucala, Ojjaara, Jemperli and Trelegy Ellipta to have driven first-quarter sales performance.
GSKPositive Net Change JNJPositive Net Change CTMXPositive Net Change ARGXPositive Net Change
biotechs earnings medical pharmaceuticals vaccines
Here's How Charles River is Placed Just Ahead of Q1 Earnings
by Zacks Equity Research
CRL's first-quarter 2025 performance is expected to have been hurt by a challenging biopharmaceutical environment.
CRLPositive Net Change CORPositive Net Change ANIPPositive Net Change HIMSNegative Net Change
earnings medical medical-devices
Zoetis Gears Up to Report Q1 Earnings: Here's What to Expect
by Zacks Equity Research
ZTS' higher companion animal product sales are likely to have driven revenues in first-quarter 2025 in both the United States and International segments.
NVAXPositive Net Change ZTSPositive Net Change CTMXPositive Net Change ARGXPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
GYN Surgical Division Likely to Drive Hologic's Q2 Earnings
by Zacks Equity Research
HOLX's second-quarter fiscal 2025 performance is likely to have benefited from expanding breast health offerings.
HOLXNegative Net Change CORPositive Net Change ANIPPositive Net Change HIMSNegative Net Change
earnings medical medical-devices
4 Top Value Stocks to Invest in as US-Global Trade Talks Unfold
by Sumit Singh
Value investing is essentially about selecting cheap but fundamentally sound stocks. STNE, CSV, ASB & PFE boast low P/CF ratios.
PFEPositive Net Change CSVNegative Net Change ASBNegative Net Change STNENegative Net Change
computers consumer-staples finance medical
The Zacks Analyst Blog Highlights Abbott Laboratories, Boston Scientific and Medtronic
by Zacks Equity Research
Abbott Laboratories, Boston Scientific and Medtronic are included in this Analyst Blog.
ABTPositive Net Change BSXPositive Net Change MDTPositive Net Change
medical
Zacks Industry Outlook Highlights Honeywell, 3M, Carlisle and Griffon
by Zacks Equity Research
Honeywell, 3M, Carlisle and Griffon have been highlighted in this Industry Outlook article.
HONNegative Net Change MMMPositive Net Change CSLPositive Net Change GFFPositive Net Change
medical
New Strong Sell Stocks for April 28th
by Zacks Equity Research
CCS, ARMP and CABO have been added to the Zacks Rank #5 (Strong Sell) List on April 28, 2025.
CCSPositive Net Change CABONegative Net Change ARMPPositive Net Change
construction consumer-discretionary medical
Top Stock Reports for Walmart, Toyota Motor & Boston Scientific
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Walmart Inc. (WMT), Toyota Motor Corp. (TM) and Boston Scientific Corp. (BSX), as well as a micro-cap stock Autoscope Technologies Corp. (AATC).
BSXPositive Net Change NKENegative Net Change TMNegative Net Change WMTPositive Net Change CBPositive Net Change SAPNegative Net Change AATCNegative Net Change
auto-tires-trucks business-services medical retail
Implied Volatility Surging for Astrana (ASTH) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Astrana (ASTH) stock based on the movements in the options market lately.
ASTHPositive Net Change
medical
Tariffs Cast a Shadow on Abbott's 2025 View: Time to Sell ABT Stock?
by Urmimala Biswas
With certain devices being imported into the United States from overseas, tariff-induced cost pressure is set to rise for Abbott from the third quarter of 2025.
ABTPositive Net Change BSXPositive Net Change MDTPositive Net Change
earnings-outlook earnings-report healthcare medical medical-devices
HCA Healthcare Q1 Earnings Beat on Growing Patient Volumes
by Zacks Equity Research
HCA continues to witness growth in reported and same-facility admissions. The company reaffirms 2025 guidance.
HCAPositive Net Change ADUSPositive Net Change OPCHPositive Net Change AVAHNo Net Change
earnings finance medical
Exelixis' Q1 Earnings: Will Cabometyx Maintain Momentum?
by Zacks Equity Research
Investors will likely focus on the demand for Cabometyx and pipeline updates when EXEL reports Q1 results.
AZNPositive Net Change VRTXPositive Net Change EXELPositive Net Change ARGXPositive Net Change
biotechnology biotechs medical pharmaceuticals
Centene Q1 Earnings Beat Estimates on Marketplace Business Strength
by Zacks Equity Research
CNC's Q1 results benefit from improved premiums as a result of a strong PDP business, partly offset by elevated operating costs. It currently expects 2025 premium and service revenues within $164-$166 billion.
TMOPositive Net Change MOHPositive Net Change CNCPositive Net Change ELVPositive Net Change
earnings medical
AbbVie Beats on Q1 Earnings & Sales, Raises '25 EPS View
by Zacks Equity Research
ABBV's first-quarter earnings and sales beat estimates. The company raises its EPS guidance based on the strong sales performance of immunology drugs Rinvoq and Skyrizi.
RHHBYPositive Net Change JNJPositive Net Change ABBVPositive Net Change
biotechs earnings medical pharmaceuticals
Here's Why You Should Hold the GEHC Stock in Your Portfolio for Now
by Zacks Equity Research
GE HealthCare's continued focus on innovations, acquisitions and partnerships raises optimism about the stock.
MASINegative Net Change FMSPositive Net Change GKOSPositive Net Change GEHCPositive Net Change
medical medical-devices
Integer Holdings Q1 Earnings & Revenues Beat Estimates, Margins Expand
by Zacks Equity Research
ITGR tops first-quarter estimates with strong sales and EPS growth. Margins expand, driven by new products, acquisitions, and operational efficiency.
MASINegative Net Change FMSPositive Net Change GKOSPositive Net Change ITGRNegative Net Change
earnings medical medical-devices
MMSI Stock Declines Despite Q1 Earnings Beating Estimates, Margins Up
by Zacks Equity Research
Merit Medical benefits from revenue growth in both segments and the majority of its product categories within its Cardiovascular unit in the first quarter of 2025.
BSXPositive Net Change RMDNegative Net Change MMSINegative Net Change EHCPositive Net Change
earnings medical medical-devices
Can Moderna Keep the Beat Streak Alive This Earnings Season?
by Zacks Equity Research
When MRNA reports first-quarter earnings, investors will likely focus on pipeline updates.
MRKPositive Net Change MRNAPositive Net Change CTMXPositive Net Change ARGXPositive Net Change
biotechs medical messenger-rna pharmaceuticals vaccines
Recursion Pharmaceuticals to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
RXRX is expected to provide updates on its oncology and rare disease clinical-stage pipeline in its first-quarter 2025 earnings release, given the absence of a marketed product.
NVAXPositive Net Change CTMXPositive Net Change ARGXPositive Net Change RXRXNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
Earnings Data Deluge
by Zacks Equity Research
Earnings Data Deluge
AMZNNegative Net Change AAPLPositive Net Change MSFTPositive Net Change CLNegative Net Change ANNegative Net Change LAZNegative Net Change ABBVPositive Net Change METANegative Net Change
consumer-staples finance medical tech-stocks